风险分析指数与修改脆弱指数:耳鼻喉外科手术后的结果
Lauran K Evans1, Carine Tamamian2, Desiree Delavary3
1Department of Head and Neck Surgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
The Laryngoscope
|August 1, 2025
概括
临床风险分析指数 (RAI-C) 比修改的5项脆弱性指数 (MFI-5) 更好地预测耳鼻喉外科手术的术后结果. 建议RAI-C用于脆弱性研究和患者护理规划.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 老年医学 老年医学
- 手术结果研究研究.
背景情况:
- 患者的虚弱显著影响术后的结果.
- 修改后的5项脆弱性指数 (MFI-5) 和临床风险分析指数 (RAI-C) 是常见的脆弱性评估工具.
- 这些指数在耳鼻喉科的直接比较以前没有进行过.
研究的目的:
- 为了比较MFI-5和RAI-C在耳鼻喉科术后预测结果的预测性能.
- 确定哪个脆弱指数是优越的,用于识别头手术后面临不良事件风险的患者.
主要方法:
- 对1209名接受耳鼻喉外科手术的患者进行了回顾性图表审查.
- 利用千平方分析和接收器运行特征 (ROC) 曲线来评估预测能力.
- 在预测术后并发症和30天再入院方面比较MFI-5和RAI-C.
主要成果:
- RAI-C确定了23%的患者是脆弱的,而MFI-5确定了21%.
- RAI-C预测手术后并发症的几率增加了5.7倍 (p < 0.0001),而MFI-5则没有.
- 这两种指数都预测了类似的30天再入院 (AUC ~0.76-0.77),但RAI-C显示了其他结果的优异预测.
结论:
- 与耳鼻喉科外科手术中MFI-5相比,RAI-C在术后预测结果方面表现优越.
- RAI-C评估对于脆弱性研究,治疗计划和管理患者期望非常有价值.
- 这些发现支持将RAI-C纳入风险手术群体的常规临床实践.
更多相关视频
09:07Author Spotlight: Advancing Endoscopic Ossiculoplasty – Techniques, Innovations, and Practical Guidance for Clinical Integration
Published on: January 26, 2024
2.6K
07:06Endaural Endoscopic Atticoantrotomy Retrograde Mastoidectomy using a Constant Suction Bone-drilling Technique
Published on: May 23, 2021
3.9K
相关概念视频
01:09Odds Ratio
261
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
261
01:20Comparing the Survival Analysis of Two or More Groups
289
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
289
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
176
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
176
01:12Relative Risk
348
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
348
01:21Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456